Frank McCormick

Leidos (United States) — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

129h-index80.2kcitations786works4.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Protein Kinase Regulation and GTPase Signaling(167), Cancer-related Molecular Pathways(106), Melanoma and MAPK Pathways(103), PI3K/AKT/mTOR signaling in cancer(100), Virus-based gene therapy research(54)

Publications785 total

Supplementary Table S1 from Discovery of BBO-8520, a First-In-Class Direct and Covalent Dual Inhibitor of GTP-Bound (ON) and GDP-Bound (OFF) KRAS<sup>G12C</sup>
2025Open Access
Supplementary Figure S4 from Discovery of BBO-8520, a First-In-Class Direct and Covalent Dual Inhibitor of GTP-Bound (ON) and GDP-Bound (OFF) KRAS<sup>G12C</sup>
2025Open Access
Supplementary Figure S5 from Discovery of BBO-8520, a First-In-Class Direct and Covalent Dual Inhibitor of GTP-Bound (ON) and GDP-Bound (OFF) KRAS<sup>G12C</sup>
2025Open Access
Supplementary Figure S1 from Discovery of BBO-8520, a First-In-Class Direct and Covalent Dual Inhibitor of GTP-Bound (ON) and GDP-Bound (OFF) KRAS<sup>G12C</sup>
2025Open Access
Supplementary Material and Methods from Discovery of BBO-8520, a First-In-Class Direct and Covalent Dual Inhibitor of GTP-Bound (ON) and GDP-Bound (OFF) KRAS<sup>G12C</sup>
2025Open Access
Data from Discovery of BBO-8520, a First-In-Class Direct and Covalent Dual Inhibitor of GTP-Bound (ON) and GDP-Bound (OFF) KRAS<sup>G12C</sup>
2025Open Access
Structural insights into isoform-specific RAS-PI3Kα interactions and the role of RAS in PI3Kα activation
Nature Communications·2025· 18 citedOpen Access
Discovery of BBO-8520, a First-In-Class Direct and Covalent Dual Inhibitor of GTP-Bound (ON) and GDP-Bound (OFF) KRASG12C
Cancer Discovery·2024· 33 citedOpen Access
The prominent pervasive oncogenic role and tissue specific permissiveness of RAS gene mutations
Scientific Reports·2024· 2 citedOpen Access
Comprehensive structure-function analysis reveals gain- and loss-of-function mechanisms impacting oncogenic KRAS activity
2024· 7 citedOpen Access
Contributors
Elsevier eBooks·2024Open Access
Foreword
Elsevier eBooks·2024Open Access
Introduction
Elsevier eBooks·2024Open Access
Inhibition and degradation of NRAS with a pan-NRAS monobody
Oncogene·2024· 7 citedOpen Access
Synergistic effects of RPT1G, a first-in-class small molecule NAMPT inhibitor, with venetoclax and olaparib in hematological malignancies.
Journal of Clinical Oncology·2024· 1 cited
Abstract RF02-02: BBO-10203, a first-in-class, orally bioavailable, selective covalent small molecule that inhibits RAS-driven PI3Kalpha activity without affecting glucose metabolism
Cancer Research·2024· 6 cited
Abstract ND07: BBO-8520, a first-in-class, direct inhibitor of KRASG12C (ON), locks GTP-bound KRASG12C in the state 1 conformation resulting in rapid and complete blockade of effector binding
Cancer Research·2024· 10 cited
Abstract 2080: SOS1 inhibition is an effective therapeutic strategy in SOS1-mutant cancer
Cancer Research·2024
A Top-Down Proteomic Assay to Evaluate KRAS4B-Compound Engagement
Analytical Chemistry·2024· 8 citedOpen Access
Structural dynamics of RAF1-HSP90-CDC37 and HSP90 complexes reveal asymmetric client interactions and key structural elements
Communications Biology·2024· 16 citedOpen Access
← Previouspage 2 of 40Next →

Frequent Co-authors

George A. Martin(5), Joe W. Gray(4), David Stokoe(4), Gideon Bollag(4), Marc Symons(4), Osamu Tetsu(3), Henry R. Bourne(3), David H. Kirn(3), D.A.R. Sanders(2), Ilya Shmulevich(2), Thomas J. Giordano(2), Richard M. Neve(2), Nora Bayani(2), Paul T. Spellman(2), Donna G. Albertson(2), Stephen P. Ethier(2), Angelica Williams(2), Carla Heise(2), Adam Sampson-Johannes(2), Meg Trahey(2)